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Abstract
AIM: To clarify the impact of cytomegalovirus (CMV) 
activation and antiviral therapy based on CMV antigen 
status on the long-term clinical course of ulcerative 
colitis (UC) patients.
METHODS: UC patients with flare-up were divided 
into CMV-positive and -negative groups according to 
the CMV antigenemia assay. The main treatment strat-
egy provided for the patients in the CMV-positive group 
comprised a dose reduction of corticosteroids and ad-
ministration of ganciclovir.
RESULTS: The median number of days to initial remis-
sion was significantly greater for the patients in the 
CMV-positive group (21 d vs  16 d, P  = 0.009). Howev-
er, the relapse rate after remission and colectomy rate 
during more than 30 mo of observation did not differ 
between the two groups. Multivariate analysis revealed 
that administration of ganciclovir was the only indepen-
dent factor for avoiding colectomy in patients of the 
CMV-positive group.
CONCLUSION: CMV antigen status did not significant-
ly affect the long-term prognosis in UC patients under 
treatment with appropriate antiviral therapy.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Cytomegalovirus (CMV) reactivation has a del-
eterious effect in patients with ulcerative colitis (UC). 
Although antiviral therapy for CMV antigen-positive UC 
patients may be effective in the short-term, the long-
term prognosis of UC patients with CMV treated by 
antiviral agents remains unknown. Our study revealed 
that positive CMV antigen status is likely to prolong 
time to remission in the treatment of flare-up of UC; 
however, long-term prognosis, including colectomy 
rate, was not affected by CMV antigen status treated 
with antiviral agents. Ganciclovir use is an independent 
factor for avoidance of colectomy in CMV antigen-posi-
tive UC patients.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel 
disease (IBD) characterized by periods of  remission and 
clinical relapses, the affected mucosa spreading from 
the rectum to the proximal large intestine, diffusely, cir-
cumferentially and continuously. The symptoms include 
bloody diarrhea, fever, tachycardia, anemia, and colicky 
abdominal pain[1]. In this decade, anti-tumor necrosis 
factor-α (TNF-α) antibodies, calcineurin inhibitors and 
apheresis, in addition to amino-salicylates and cortico-
steroids, have been used widely for the treatment of  
UC with relapse. The clinical course of  UC patients has 
improved, but 20%-30% of  patients with total colitis 
still come to colectomy[2-4]. Although the mortality of  
UC patients is not significantly higher than standardized 
mortality ratios of  non-IBD populations, the cause of  
UC remains uncertain and there is still room for further 
research[5-7].
Cytomegalovirus (CMV) reactivation is sometimes as-
sociated with relapse of  UC. A number of  reports have 
debated the pathogenicity of  CMV in UC patients and 
there are contrasting hypotheses that this is a pathogenic 
virus exacerbating the clinical course of  IBD patients and 
that it is “an innocent bystander” and does not contribute 
to increased morbidity and mortality of  UC patients[5-14]. 
As the influence of  CMV infection on the UC patient re-
mains uncertain, the clinical management of  UC patients 
with CMV reactivation has not yet been standardized. In 
this context, some studies reported that antiviral therapy 
decreased the colectomy rate and mortality of  UC pa-
tients with CMV reactivation[8,9]. Meanwhile, another 
reported that there were no significant differences in the 
rates of  remission and colectomy between UC patients 
with and without CMV[10]. Moreover, it is problematic 
that there are so few studies indicating the long-term 
prognosis of  UC patients complicated with CMV.
Another important problem regarding CMV infec-
tion of  UC patients is the diagnostic modality. There 
are several diagnostic techniques for CMV “infection”, 
including endoscopy, histology, serology, viral culture, 
CMV antigenemia assay and CMV DNA testing, which 
have varying sensitivity and specificity. At this point, im-
munohistochemistry (IHC) or CMV DNA testing of  
intestinal mucosa tissue is recommended for diagnosis 
of  CMV “disease” in IBD patients, according to several 
guidelines[15-17]. However, these require colonoscopy and 
the former may have too low sensitivity and the latter 
too high sensitivity for the indication of  antiviral ther-
apy[8,16,18]. The CMV antigenemia assay has been widely 
used for pre-emptive therapy in hematopoietic stem 
cell transplantation[19-22]. In the field of  UC, in contrast, 
relatively few studies evaluated the clinical significance 
of  the CMV antigenemia assay, e.g., for decision of  ad-
ministration of  antiviral therapy[8,10]. However, the CMV 
antigenemia assay has advantages in that it is relatively 
inexpensive and facilitates monitoring of  CMV activity 
continuously without endoscopy. Moreover, the assay 
may have less sample bias than examinations using tissues 
from the colon. 
We have examined the CMV status in relapse of  UC 
patients using the CMV antigenemia assay and treatment 
strategies were determined based on the CMV antigen 
status. The mainstay of  our strategy for the patients 
found to be CMV antigen positive comprised ganciclovir 
administration and dose reduction of  corticosteroids. 
The patients treated according to the strategy were 
followed-up at our institute for a relatively long period 
and the disease course of  those patients may reveal the 
impact of  CMV reactivation and antiviral therapy on the 
long-term prognosis of  UC patients with CMV. 
In this study, therefore, we investigated the long-term 
disease course of  UC patients diagnosed as CMV-positive 
and -negative using the CMV antigenemia assay. The aim 
of  this study was to clarify the impact of  CMV antigen 
and antiviral therapy on the UC patients’ prognosis: re-
mission rate, relapse rate and colectomy rate.
MATERIALS AND METHODS
Patients
We retrospectively analyzed UC patients who were treat-
ed for their first-attack or relapse of  disease at Okayama 
University Hospital from April 2004 to November 2011. 
Inclusion criteria were disease activity of  Lichtiger’s clini-
cal activity index (CAI) 7 or more and having results of  
CMV antigen status evaluated by CMV antigenemia as-
say, and 121 patients met the criteria[23]. Of  these patients, 
3 who underwent emergency colectomy prior to the 
outcome of  the CMV antigenemia assay were excluded. 
The remaining 118 patients were treated according to the 
strategy based on CMV antigen status, as shown below, 
and clinical, operative, pathological and treatment data 
were obtained from the patients’ medical records. 
CMV evaluation
CMV antigen status was evaluated using the CMV-pp65 
antigenemia assay (SRL, Tokyo, Japan). The test is based 
on immunocytochemical detection of  CMV immediate 
early antigens in blood leukocytes. The results were ex-
pressed as the number of  CMV-pp65-positive cells per 
5 × 104 leukocytes and reported on the day following 
blood submission to the laboratory, although this took a 
few days at weekend. A positive result from the CMV an-
tigenemia assay was defined as detection of  one or more 
CMV-pp65-positive cells. Patients were divided into two 
groups according to CMV antigen status: CMV-positive 
group and CMV-negative group. CMV antigenemia assay 
was performed when treatment was started in relapse of  
UC patients and disease condition did not become better 
despite administration of  immunosuppressive therapy. 
CMV antigenemia was usually measured once two weeks 
in patients with positive CMV antigen on the initial assay. 
Those of  whom disease condition worsened after start-
ing ganciclovir received the assay once a week. 
If  general condition permitted, we performed colo-
noscopy around the time of  the CMV antigenemia assay 
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and took biopsies for hematoxylin and eosin staining to 
search for CMV inclusion bodies and for IHC staining 
with a monoclonal antibody against CMV by means of  
an automated preparation and processing system, Ven-
tana® (Roche Diagnostics, Tokyo, Japan). 
Treatment strategy
In our hospital, UC patients were treated based on the 
guidelines published by the British Society of  Gastroen-
terology, the European Crohn’s and Colitis Organization, 
and the American College of  Gastroenterology[15,17,24]. In 
general, a sufficient dose of  corticosteroids, 0.5-1 mg/kg 
per day of  prednisolone for patients with moderate ac-
tivity and 1-1.5 mg/kg per day for patients with severe 
activity, was administered with a target period set at two 
weeks and then gradually reduced by 5-10 mg/d at week-
ly intervals until a daily dose of  20 mg was reached. In 
patients with a steroid-refractory or -dependent course, 
another treatment, such as apheresis, a calcineurin inhibi-
tor or anti-TNF-α antibody, was started according to 
their disease severity and treatment history. In this study, 
anti-TNF-α antibody was used less frequently because 
infliximab for UC was approved in Japan in June 2010. 
The effectiveness of  additional treatments was also 
evaluated within about two weeks. Antiviral therapy with 
ganciclovir was not generally administered for patients in 
the CMV-negative group. However, antiviral therapy was 
administered for some patients who underwent acute ex-
acerbation with endoscopic findings suggestive of  CMV 
infection such as large, deep, or longitudinal ulcers[25].
When patients were found to be CMV antigen posi-
tive, ganciclovir administration with reduction of  the 
dose of  corticosteroids was considered to be the first 
choice. However, the antiviral agent was not provided 
for cases with mild disease activity or for cases for which 
conventional treatment without ganciclovir appeared to 
be effective. As the next step, steroid-refractory patients 
received apheresis, anti-TNF-α antibody, or a calcineurin 
inhibitor after diminishment of  CMV antigen. 
Evaluation of disease course
Remission, relapse, and colectomy rates were compared 
between the CMV-positive and -negative groups. The 
severity was expressed according to Truelove and Witt’s 
criteria[26]. State of  relapse was defined as CAI score 7 or 
more[23]. The definition of  remission meets the CAI score 
4 or less without any abdominal pains and bloody stools. 
Short-term clinical courses were evaluated according to 
patient status within 8 wk of  examination of  CMV an-
tigen status, while long-term clinical courses were deter-
mined at the last visit before March 2012 or the time of  
colectomy.
Ethical considerations
This retrospective analysis was approved by the institu-
tional review board of  Okayama University Graduate 
School of  Medicine, Dentistry, and Pharmaceutical Sci-
ences and all the patients and subjects were included after 
obtaining their written informed consent. There were no 
conflicts of  interest or sponsors of  this study.
Statistical analysis
Patient characteristics were compared using the χ 2 test, 
Fisher’s exact test and Mann-Whitney U test. Analyses 
of  remission, relapse and colectomy rates were carried 
out using the method of  Kaplan and Meier. Statistical 
comparison was carried out by Log-rank test. Univariate 
and multivariate analysis using a Cox proportional hazard 
model were also conducted. P value < 0.05 was consid-
ered statistically significant. All statistical analyses were 
performed using JMP ver.9 software (SAS Institute, Cary, 
NC, United States). 
RESULTS
Patient characteristics
The clinical characteristics of  analyzed patients are 
summarized in Table 1. A total of  118 UC patients 
with known CMV antigen status were treated during 
the study period; 40 were included in the CMV-positive 
group and 78 were in the CMV-negative group. CMV 
antigen was detected more frequently in male patients (P 
= 0.009). The dose of  corticosteroids at the beginning 
of  the treatment was significantly higher for the patients 
in the CMV-positive group than those in the CMV-
negative group (35 mg/d of  prednisolone vs 20 mg/d, P 
= 0.0003). CMV status of  all the CMV-positive patients 
except those who underwent colectomy in a short term 
became negative, regardless of  ganciclovir administra-
tion or not. The average period between the start of  
therapy and measurement of  CMV antigenemia assay 
was 10.8 ± 13.4 d.
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  Characteristics CMV Ag+ 
(n  = 40)
CMV Ag- 
(n  = 78)
P  value
  Gender   0.009
     Male 26 31
     Female 14 47
  Age(yr), median (range)   45 (14-79)    36 (12-87) 0.10
  Duration of disease (yr),
  median (range)
  1.5 (0.1-28) 4.6 (0-38) 0.23
  Disease activity  0.191
     Mild   2   8
     Moderate 15 35
     Severe 23 35
  Lichtiger’s CAI, 
  median (range)
11 (7-19)  13 (7-21) 0.15
   Extent of disease 0.31
     Total colitis 33 58
     Left-sided   7 20
  Dose of prednisolone 
  (mg/d), median (range)
35 (0-80)    20 (0-100)     0.0003
  Follow-up period (yr),
  median (range)
   3.2 (0.1-9.3)     2.8 (0.1-9.7) 0.66
Table 1  Characteristics of the study population (n  = 118)
1Overall P value. By χ 2 test, Fisher’s exact test, and Mann-Whitney U test. 
CMV Ag: Cytomegalovirus antigenemia assay; CAI: Clinical activity 
index. 
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cineurin inhibitors were used relatively frequently. 
Short-term remission rates according to CMV antigen 
status
In the CMV-positive group, 25 (62.5%) patients went into 
remission and 5 (12.5%) received colectomy during the 
short-term treatment. The remaining 10 (25%) patients 
improved, but did not fulfill the criteria of  remission. 
Among the CMV-negative group, on the other hand, 
54 (69.2%) patients entered remission successfully, 14 
(17.9%) improved, and 10 (12.8%) underwent colectomy 
in the short-term (Figure 1, center part). 
Two types of  the Kaplan-Meier curves for the rate 
of  remission induction are shown (Figure 2). Figure 2A 
indicates the remission rate from the starting day of  the 
remission-induction therapy and Figure 2B shows from 
the day when the CMV antigen status was determined. 
Both curves show the better clinical course in the CMV-
negative group (P = 0.0006 and P = 0.03, respectively, 
Log-rank test). The median number of  days to remis-
sion from the start of  the treatment with our strategy 
was significantly greater for the patients in the CMV-
positive group than those in the CMV-negative group (21 
d vs 16 d, P = 0.009, Mann-Whitney U test). In addition, 
we analyzed remission rate from the starting day of  the 
remission-induction therapy between the two groups; one 
group was limited to CMV-positive patients administered 
ganciclovir and another was CMV-negative patients not 
administered ganciclovir. These curves showed the better 
clinical course in the CMV-negative group, too (P = 0.03, 
Log-rank test). 
The correlation between CMV antigen status and 
IHC for CMV in the colonic mucosa was examined using 
49 patients who underwent colonoscopy around the time 
of  the CMV antigenemia assay. Of  the 23 patients in the 
CMV-positive group, 9 (39.1%) were positive for IHC. 
On the other hand, 25 (96.2%) of  the 26 patients in the 
CMV-negative group were negative for IHC. The results 
of  the CMV antigenemia assay were closely correlated 
with IHC of  inflamed colon mucosa for CMV (P = 0.003, 
Fisher’s exact test). Taking IHC as the gold standard, 
positive CMV antigen status predicted positive IHC with 
90% sensitivity and 64% specificity. 
Initial treatment for patients 
Figure 1 is a flow chart of  the clinical courses of  the 118 
patients treated according to the strategy based on CMV 
antigen status. Of  the 38 patients in the CMV-positive 
group who had received corticosteroids, 30 (78.9%) 
underwent dose reduction of  corticosteroids. The re-
maining 8 patients did not undergo dose reduction of  
corticosteroids; 3 received colectomy in the early period 
and 5 showed a marked response to the corticosteroids. 
Twenty-eight (70%) patients in the CMV-positive group 
received ganciclovir infusion. On the other hand, 68 
(87.2%) of  the 78 patients in the CMV-negative group 
received corticosteroids without any dose reductions. Six 
(7.7%) patients in the CMV-negative group were admin-
istered ganciclovir infusion because CMV reactivation 
was suspected, based on specific endoscopic findings and 
clinical refractoriness to the first-line therapy with clinical 
symptoms worsening. In both groups, apheresis and cal-
118  UC patients with flare-up with CAI score 7 or more
40  CMV Ag+
38
28
23
10
  1
PSL (30 dose reduction)
GCV
Apheresis
CNIs
Anti-TNF-α  
78  CMV Ag-
68
36
27
6
4
PSL      
Apheresis
CNIs
GCV
Anti-TNF-α 
Short-term
clinical course 
Long-term
clinical course
25 remission 10 improvement 5 colectomy 54 remission 14 improvement 10 colectomy
15 continuous
clinical remission
13 relapse 7 colectomy
34 continuous
clinical remission
20 relapse 14 colectomy
Figure 1  Clinical course of ulcerative colitis patients treated according to the status of cytomegalovirus antigen. A flow chart of the clinical courses of the 
118 patients according to the strategy based on cytomegalovirus (CMV) antigen status is shown. UC: Ulcerative colitis; CMV Ag: Cytomegalovirus antigenemia assay; 
PSL: Prednisolone; CAI: Clinical activity index; GCV: Ganciclovir; CNIs: Calcineurin inhibitors; TNF-α: Tumor necrosis factor-α.
Inokuchi T et al . Ulcerative colitis and cytomegalovirus antigen
14 10
1 1
3
6
29 16
9 5
4
5
513 January 14, 2014|Volume 20|Issue 2|WJG|www.wjgnet.com
Relapse rate after successful remission induction 
according to CMV antigen status
In the CMV-positive group, 14 (56%) of  the 25 patients 
who had gone into remission within the short-term 
maintained that status. In contrast, only one (10%) of  the 
10 patients with improvement in the short-term entered 
remission afterwards. Meanwhile, in the CMV-negative 
group, 34 (50%) of  68 patients who avoided colectomy in 
the short-term could maintain continuous clinical remis-
sion (Figure 1, lower part).
The rate of  relapse after successful remission induc-
tion with the initial treatment did not differ between the 
patients in the CMV-positive and -negative groups (Figure 
3; P = 0.36, Log-rank test). Among 20 patients in the 
CMV-positive group who underwent relapse or colec-
tomy after the initial induction of  remission, 2 became 
positive for CMV antigen again. These patients were in-
tractable to any therapy, including anti-TNF-α antibodies, 
and calcineurin inhibitors, and continued to suffer from 
chronic symptoms during the study period. None of  the 
34 patients in the CMV-negative group who relapsed or 
underwent colectomy after the initial remission became 
positive for CMV antigen.
Colectomy rate according to CMV antigen status
The cumulative colectomy rate according to CMV an-
tigen status is shown in Figure 4. Twelve (30%) in the 
CMV-positive patients and 24 (30.8%) in the CMV-
negative patients underwent colectomy during the ob-
servation period and there was no significant difference 
in the colectomy rate between the two groups (Figure 4; 
P = 0.81, Log-rank test, median observation period: 31 
mo). No independent risk factors for colectomy could 
be identified among demographic, treatment and disease 
parameters including CMV antigen status in the analysis 
of  all 118 patients with or without CMV antigen (Table 
2). Whereas, for patients in the CMV-positive group, mul-
tivariate analysis using parameters including ganciclovir 
administration, dose reduction of  corticosteroids and 
number of  CMV antigen revealed that administration of  
ganciclovir at the start of  therapy was the only factor cor-
related with avoidance of  colectomy (Table 3; OR = 0.04; 
95%CI: 0.01-0.50). 
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Figure 2  Short-term remission rate according to cytomegalovirus antigen status. Kaplan-Meier curves for the rate of induction of remission. A: The remission 
rate from the day of starting the remission-induction therapy; B: The remission rate from the day when the status of cytomegalovirus (CMV) antigen was determined. 
Both curves show the better clinical course in the CMV-negative group (P = 0.0006 and P = 0.03, respectively, Log-rank test). The median number of days to remis-
sion from the start of the treatment based on our strategy was significantly greater for patients in the CMV-positive group than for patients in the CMV-negative group (21 
d vs 16 d, P = 0.009, Mann-Whitney U test). 
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Figure 3  Relapse rate after successful induction of remission accord-
ing to cytomegalovirus antigen status. The rate of relapse after successful 
induction of remission with the initial treatment was shown. The rate of relapse 
after successful induction of remission did not differ between the patients in the 
cytomegalovirus (CMV)-positive and -negative groups (P = 0.36, Log-rank test). 
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Figure 4  Colectomy rate according to cytomegalovirus antigen status. 
The cumulative colectomy rate according to cytomegalovirus (CMV) antigen 
status. Twelve (30%) of the CMV-positive patients and 24 (30.8%) of the CMV-
negative patients underwent colectomy during the observation period and no 
difference in colectomy rate was observed between the two groups (P = 0.81, 
Log-rank test, median observation period: 31 mo). 
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DISCUSSION
We analyzed data from UC patients with flare-up and 
who were treated according to a strategy based on the 
CMV antigen status and demonstrated the clinical cours-
es of  CMV antigen-positive and -negative patients. In UC 
patients with flare-up, CMV antigen positive status signif-
icantly prolonged the time to remission from the start of  
treatment but did not affect the relapse or colectomy rate. 
In addition, ganciclovir administration was a significant 
factor correlated with avoidance of  colectomy in patients 
with positive CMV antigen status.
It has been suggested that CMV is pathogenic for 
UC patients and causes clinical condition of  UC patients 
with relapse to become worse and complicate. In fact, 
several small scale studies indicated that UC patients with 
CMV infection had higher colectomy rates than those 
without CMV. Moreover, treatment of  CMV infection 
by ganciclovir can improve the clinical outcome of  those 
patients[8,27-29]. Although a few reports indicated the pos-
sibility of  CMV being an innocent bystander in the exac-
erbation of  UC[10], CMV can affect some of  UC patients 
deleteriously. However, the long-term effect of  CMV in-
fection and antiviral therapy on the prognosis of  UC pa-
tients has not been elucidated completely. In this context, 
our results, including the long-term disease course of  UC 
patients with CMV infection, should have a great impact 
on the clinical practice of  UC. 
We showed that patients with CMV infection were 
less likely to enter remission in the short-term. This result 
is consistent with those of  previous reports[9,27]. In con-
trast, however, no significant difference in colectomy rate 
was observed between patients with and without CMV, 
even in the short-term. In this context, the CMV antigen-
emia assay could reliably detect CMV “disease” which re-
quires antiviral therapy. In our finding, use of  ganciclovir 
is not always correlated with CMV negative conversion in 
short-term but a predictor of  avoidance of  colectomy in 
long-term. These suggest that use of  ganciclovir exerts 
clinical effectiveness in long-term follow-up, e.g., avoiding 
exacerbation and/or relapse after remission, for a portion 
of  patients with CMV.
In term of  diagnosis regarding CMV infection in UC 
patients, IHC or CMV DNA testing in the intestinal mu-
cosa tissue is recommended as a diagnosis of  CMV “dis-
ease” in IBD patients according to several guidelines[15-17]. 
In particular, CMV DNA testing would be a very useful 
method if  the correct cut-off  level of  CMV DNA load 
was established[30]. However, CMV DNA testing is expen-
sive and needs colonoscopy with biopsy that has a risk 
of  bleeding or perforation in severely ill UC patients. In 
addition, there is a sample bias in taking tissues from the 
mucosa. CMV DNA testing in blood sample may be con-
venient, but the method and cutoff  values remain to be 
standardized. On the other hand, the CMV antigenemia 
assay is less expensive and facilitates monitoring of  CMV 
activity continuously without endoscopy. Moreover, there 
is less sample bias than in taking from colon tissue. We 
confirmed that the results of  the antigenemia assay were 
consistent with the results of  IHC for CMV, although the 
specificity for IHC was relatively low. In fact, lower speci-
ficity may indicate overestimation of  CMV disease by the 
antigenemia assay. Therefore, our strategy may provide 
unnecessary antiviral therapy for part of  patients. 
Reduction of  the dose of  corticosteroids is another 
aspect of  our treatment strategy for UC patients with 
CMV. There has been no consensus regarding whether 
immunosuppressive therapies should be continued or 
discontinued, and whether the dose of  corticosteroids 
should be increased or decreased for UC patients with 
CMV. Some have reported cases with continuation of  the 
immunomodulating drugs[8,29], while others have discon-
tinued the immunosuppressive therapies[27,28]. Interest-
ingly, all of  these studies showed good clinical courses 
whether immunosuppressive therapies were ongoing or 
not. In addition, our results indicated that reduction of  
the dose of  corticosteroids and immunosuppressive ther-
apies were not significant factors in multivariate analysis 
for avoiding colectomy both in the short and long-term. 
This suggests that status of  immunosuppressive thera-
  Risk factor Risk ratio 95%CI P  value
Lower Upper
  Gender (male) 0.97 0.59 1.59 0.89
  Age (> 40 yr) 1.13 0.70 1.82 0.61
  Duration of disease
  (> 3 yr)
0.99 0.61 1.61 0.97
  Severity (severe) 1.24 0.74 2.08 0.42
  Extent of disease
  (total colitis)
1.21 0.68 2.23 0.51
  CMV Ag (+) 0.64 0.36 1.13 0.12
  Apheresis use 0.71 0.44 1.17 0.18
  CNI use 1.11 0.63 1.92 0.73
Table 2  Multivariate analysis of factors predictive of 
colectomy in ulcerative colitis patients
CMV Ag: Cytomegalovirus antigenemia assay; CAI: Clinical activity 
index. 
  Risk factor Risk ratio 95%CI P  value
Lower Upper
  Gender (male) 0.38 0.03 4.24 0.42
  Age (> 45 yr) 1.22 0.15 12 0.85
  Duration of disease (> 2 yr) 0.98 0.09 9.18 0.98
  Severity (severe) 8.37 0.46 751 0.17
  Extent of disease (total colitis) 2.43 0.15 118 0.55
  Apheresis use 0.87 0.08 9.59 0.91
  CNI use 0.54 0.01 10.2 0.69
  Ganciclovir use 0.04 0.01 0.5 0.01
  Dose reduction of corticosteroids 0.76 0.03 13.1 0.85
  Number of CMV Ag1 (> 3) 3.77 0.53 42.3 0.19
Table 3 Multivariate analysis of factors predictive of 
colectomy in ulcerative patients with positive cytomegalovirus 
antigen status 
1This number means the maximum of CMV Ag detected during the 
period. CMV Ag: Cytomegalovirus antigenemia assay; CAI: Clinical 
activity index. 
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pies, including the dose of  corticosteroids, may not affect 
the clinical course of  UC patients with CMV greatly, at 
least under antiviral therapy. 
The highlight of  this study is determination of  the 
long-term prognosis of  UC patients with CMV infec-
tion, including relapse rate and colectomy rate, which 
have rarely been reported. Unexpectedly, no significant 
difference was observed in overall long-term prognosis 
between patients with and without CMV. Kaplan-Meier 
curves for colectomy were almost parallel, both in the 
short-term and in the long-term, between those patients. 
These results suggest that UC patients with positive 
CMV antigen should be treated with antiviral therapy and 
that our treatment strategy may be appropriate for UC 
patients with CMV with regard to long-term prognosis. 
However, there may be two types of  rebuttal to our 
results. First, antiviral therapy may not always be required 
for UC patients with CMV. Although the efficacy of  an-
tiviral agents in CMV disease has been recognized wide-
ly[15,31,32], a previous report demonstrated that UC patients 
with CMV infection who were treated without the use 
of  antiviral agents showed similar rates of  remission and 
colectomy to UC patients without CMV[10]. However, the 
report consisted of  25 patients with CMV (4 underwent 
colectomy) and 23 patients without CMV (1 underwent 
colectomy) with an observation period of  8 wk, and such 
small number of  patients with short-term observation 
may not be sufficient to verify the appropriateness of  a 
treatment strategy without antiviral therapy. For accu-
rate validation of  the use of  antiviral agents, long-term 
follow-up data of  patients who were treated according to 
a strategy without antiviral therapy would be expected. 
However, such a treatment strategy may not be feasible 
under the guidelines which recommended antiviral thera-
py for at least a proportion of  patients with CMV.
The second problem is the appropriateness of  the 
antigenemia assay for detecting the presence of  CMV 
infection and administration of  ganciclovir. As described 
above, a positive result from the antigenemia assay may 
overestimate the necessity of  administration of  antiviral 
therapy, because specificity for IHC was relatively low. 
In this regard, Roblin et al[30] indicated 250 copies/mg of  
CMV DNA in the colonic tissue as the cutoff  for antivi-
ral therapy, based on 42 hospitalized UC patients. How-
ever, few studies indicated a correlation between CMV 
antigen status and CMV DNA in colonic tissues, perhaps 
because of  sample bias and the lack of  validation of  
the technology of  DNA testing, and therefore it is not 
known what is best as the cutoff  for antiviral therapy. 
Determination of  the optimal test modality and cutoff  
values for CMV disease in UC which requires antiviral 
therapy should be the goal of  future studies.
This study has a limitation mainly because of  the 
retrospective design. First of  all, the treatment strategy 
was not always followed. Not all of  the CMV-positive 
patients were administered ganciclovir and some of  the 
CMV-negative patients were administered ganciclovir. 
Dose reduction of  corticosteroids was not carried out for 
CMV-positive patients if  corticosteroids exerted marked 
efficacy. However, from the aspects of  ethical and moral 
standpoints, it would be difficult not to administer anti-
viral agents to severe and refractory patients with CMV 
infection on the basis of  the current evidence. In this 
regard, our retrospective analysis for the long-term prog-
nosis of  UC patients with CMV may be almost optimal 
for verifying the treatment strategy for those patients. 
There is also a limitation about patients’ selections; dose 
of  corticosteroids at the beginning of  the treatment was 
significantly lower in the CMV-negative group. The pa-
tients examined CMV status and enrolled in this study 
were suspected involvement with CMV for their refracto-
riness and endoscopic findings. In severer case which was 
suspected involvement with CMV reactivation, we would 
avoid using large dose of  PSL not to reactivate CMV. 
As a result, we chose second-line therapy such as CNIs, 
apheresis and not dose up of  corticosteroids, especially 
in CMV-negative group, CAI of  which was severer than 
positive group. In addition, CMV antigen was detected 
more frequently in male. However, I tried to stratify the 
results by gender and dose of  corticosteroids, respec-
tively, and we confirm that each result did not show a 
significant difference. 
In conclusion, our treatment strategy, which con-
sisted of  dose reduction of  corticosteroids and antiviral 
therapy, appeared to be appropriate for the treatment 
of  UC patients with CMV antigen in view of  long-term 
prognosis. More work is needed for the standardization 
of  appropriate test modalities and cutoff  values for ad-
ministration of  antiviral therapy and the administration 
policy of  immunosuppressive agents for UC patients 
with CMV. 
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